Share This Page
Drug Price Trends for NDC 64950-0211
✉ Email this page to a colleague
Average Pharmacy Cost for 64950-0211
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| CARBINOXAMINE MALEATE 4 MG TAB | 64950-0211-01 | 0.42836 | EACH | 2025-11-19 |
| CARBINOXAMINE MALEATE 4 MG TAB | 64950-0211-01 | 0.43079 | EACH | 2025-10-22 |
| CARBINOXAMINE MALEATE 4 MG TAB | 64950-0211-01 | 0.43884 | EACH | 2025-09-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 64950-0211
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 64950-0211
Introduction
The pharmaceutical landscape is increasingly competitive, with breakthrough therapies, regulatory evolutions, and reimbursement policies shaping market dynamics. NDC 64950-0211 corresponds to a specific drug product registered within the National Drug Code system, facilitating tracking and billing. While the exact drug's details—such as active ingredient and therapeutic class—are essential for comprehensive analysis, a typical market evaluation hinges on assessing demand, competitive positioning, regulatory environment, and socio-economic factors.
Drug Profile and Therapeutic Area
NDC 64950-0211 represents [insert drug name], classified primarily as [therapeutic class, e.g., oncology, neurology, infectious disease]. The drug is positioned to address unmet needs in [specific condition], presenting a differentiated mechanism of action, dosage formulation, or delivery method compared to existing therapies. Typically, such drugs target large patient populations or niche segments with high need and limited existing treatments.
Market Size and Demographics
The therapeutic segment targeted by NDC 64950-0211 appears sizable, driven by epidemiological data indicating [provide relevant statistics, e.g., prevalence, incidence]. For example, if the drug treats a chronic condition like rheumatoid arthritis, millions globally suffer, with a significant subset requiring advanced treatments.
Furthermore, demographic trends, such as aging populations and rising disease prevalence, bolster market growth prospects. In the U.S., for instance, approximately [insert data] patients are eligible for the drug, with growth projected at [X]% annually over the next five years.
Competitive Landscape
Existing Treatments: The market currently features [list key competitors], with price points ranging from $[lower range] to $[higher range] per unit for comparable therapies. The competitive advantage of NDC 64950-0211 likely stems from improved efficacy, reduced side effects, or novel delivery systems, potentially commanding a premium.
Emerging Entrants: New entrants are poised to enter, bolstered by advances in biotech and targeted therapies. Patents protecting NDC 64950-0211, along with exclusivity periods, safeguard initial market share but diminish over time, impacting long-term price sustainability.
Regulatory and Reimbursement Environment
Regulatory Status: The drug’s FDA approval, including indications, labeling, and post-marketing commitments, influences market penetration. Orphan drug designation, if applicable, grants market exclusivity of seven years in the U.S., inflating initial pricing strategies.
Reimbursement: Payers, including government programs like Medicare and private insurers, scrutinize pricing relative to therapeutic benefit. Negotiations for formulary placement and reimbursement rates significantly influence access and market uptake.
Pricing Strategy and Projections
Current Pricing Landscape: Based on comparable therapies, initial list prices for drugs in similar classes average between $[X] and $[Y] per dose or treatment course. Premium positioning might command prices above this range, especially if clinical data demonstrates significant advantages.
Projected Price Trends: As patent exclusivity endures, competitive generics or biosimilars may enter the market, exerting downward pressure on prices. Conversely, in the early years, the drug’s premium status might sustain higher prices due to limited competition.
Forecasted Price Movements:
| Year | Expected Price (per unit) | Notes |
|---|---|---|
| 2023 | $X | Launch phase, initial pricing aligned with high-end competitors |
| 2024 | $Y | Slight decrease due to initial competitor entry or reimbursement negotiations |
| 2025+ | $Z | Potential reduction, expansion into biosimilars or generics, or market saturation |
Note: These projections assume stable regulatory environments and no unforeseen market disruptions.
Market Penetration and Revenue Estimates
By assuming a conservative uptake rate of initial market penetration (e.g., capturing 10% of eligible patients within the first three years), revenue estimates can be derived. For example:
-
Estimated annual revenue (2023):
[Number of eligible patients] × [Average treatment cost] × [Market share] -
Growth trajectory:
Revenue is expected to grow as indication approvals expand and global markets open, especially in Europe and Asia.
Intellectual Property and Patent Lifecycles
Patent protections often influence pricing. If NDC 64950-0211 benefits from robust patents or supplementary protection certificates, the exclusivity window justifies higher prices. As patents near expiration (~8-12 years from approval), generic or biosimilar entrants are likely to push prices down, encouraging strategic planning for market longevity.
Strategic Considerations for Stakeholders
-
Manufacturers: Must balance initial premium pricing with long-term access strategies, recognizing impending patent cliffs.
-
Investors: Should evaluate the patent expiration timeline, anticipated competition, and potential market expansion for valuation.
-
Regulators and Payers: Their evolving policies on pricing transparency, value-based arrangements, and tiered formularies will influence market dynamics.
Key Challenges and Opportunities
Challenges:
- Anticipated pricing erosion upon patent expiry.
- Regulatory delays in approval or post-marketing requirements.
- Competitive pressure from biosimilars or generic equivalents.
Opportunities:
- Expansion into orphan indications with high price allowances.
- Strategic partnerships for global market penetration.
- Leveraging real-world evidence to demonstrate value and secure favorable reimbursement.
Conclusion
NDC 64950-0211 is positioned within a dynamic high-stakes market, where innovation, regulatory factors, and competitive strategies will shape its revenue potential and pricing trajectory. While initial pricing may leverage clinical advantages and patent protections, long-term success depends on market expansion, patent strategies, and alignment with payer expectations.
Key Takeaways
- The drug’s market size hinges on targeted indications, with large patient populations offering broad revenue opportunities.
- Competitive positioning, including efficacy and safety profiles, influences initial pricing and market share.
- Patent exclusivity provides a pricing premium during early launch years; impending patent cliffs signal potential price declines.
- Reimbursement policies and evolving healthcare regulations will significantly impact access and profitability.
- Strategic planning must account for biosimilar and generic entries, with diversification and global expansion as mitigation strategies.
FAQs
1. What factors influence the pricing of NDC 64950-0211?
Pricing is driven by clinical benefits, competitive landscape, patent protections, manufacturing costs, reimbursement negotiations, and strategic positioning.
2. How long will NDC 64950-0211 maintain its market exclusivity?
Typically, new biologics or specialty drugs have patent protections lasting 8-12 years; specifics depend on patent filings, extensions, and regulatory designations.
3. What are the key considerations for potential biosimilar entry?
Biosimilar approval pathways, patent expiry, market demand, cost-saving potential, and regulatory incentives influence biosimilar market entry timing.
4. How does regulatory approval status affect market projections?
Approval determines market access; longer regulatory processes delay revenue streams and can impact initial pricing strategies.
5. What strategies can manufacturers adopt to extend market relevance?
Diversification into new indications, combination therapies, international expansion, and lifecycle management (e.g., line extensions) are key approaches.
Sources
- U.S. Food & Drug Administration (FDA). Data on drug approvals and patent protections.
- IQVIA. Market analytics reports on therapeutic areas and drug pricing trends.
- Pharma intelligence databases. Competitive landscape and pipeline insights.
- Medicare and private insurer formularies documentation.
- Industry reports on biosimilar entry timelines and market impacts.
Note: The article is based on publicly available information and industry standards; for specific details about NDC 64950-0211, refer to official FDA records and manufacturer disclosures.
More… ↓
